Protara Therapeutics: FDA Clears IND Application for TARA-002 in Bladder Cancer
October 12 2021 - 7:56AM
Dow Jones News
By Michael Dabaie
Protara Therapeutics Inc. said the U.S. Food and Drug
Administration cleared its investigational new drug application for
TARA-002 for the treatment of non-muscle invasive bladder cancer,
sending shares higher in premarket trade.
Protara, a clinical-stage company focused on cancer and rare
diseases, said it expects to initiate a Phase 1 clinical trial of
TARA-002 in adults with high-grade NMIBC by the end of this
year.
Shares rose 24% to $8.37 early Tuesday.
The primary objective of the trial is to evaluate the safety,
tolerability and preliminary signs of anti-tumor activity of
TARA-002, with the goal of establishing a maximum tolerated dose
and recommended dose for a future Phase 2 clinical study.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
October 12, 2021 07:41 ET (11:41 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jul 2023 to Jul 2024
